APA (7th ed.) Citation

DM, B., GJ, J., CC, W., E, A., JS, H., & AM, K. (2025). MERLIN: Two-Year Results of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid. Ophthalmology, 132(2), 131. https://doi.org/10.1016/j.ophtha.2024.08.022

Chicago Style (17th ed.) Citation

DM, Brown, Jaffe GJ, Wykoff CC, Adiguzel E, Heier JS, and Khanani AM. "MERLIN: Two-Year Results of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid." Ophthalmology 132, no. 2 (2025): 131. https://doi.org/10.1016/j.ophtha.2024.08.022.

MLA (9th ed.) Citation

DM, Brown, et al. "MERLIN: Two-Year Results of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid." Ophthalmology, vol. 132, no. 2, 2025, p. 131, https://doi.org/10.1016/j.ophtha.2024.08.022.